Anthera hits another setback as its Japanese partner quits on blisibimod

Anthera Pharmaceuticals ($ANTH) is back on the hunt for a partner in Asia after Japanese drugmaker Zenyaku pulled the plug on the pair's collaboration, clouding the future for the company's lupus drug. Zenyaku is backing out of a 2014 agreement covering Anthera's blisibimod, exercising its termination clause and agreeing to return Japanese rights to the drug in January. The treatment's progress in Japan "has been disappointing," Anthera CEO Paul Truex said in a statement, as Zenyaku never enrolled any clinical trials and didn't purchase any blisibimod from its partner. But Anthera says its brief partnership provided enough in the way of financing to help fund blisibimod's future, including an ongoing late-stage study in nephropathy. More

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.